Iohexol Injection

Iohexol Injection is a non-ionic Contrast Media. Compared with a traditional
ionic Contrast Media, Iohexol Injection has an excellent molecular structure
and it can greatly improve user safety and significantly reduce adverse
reactions. The iodinated contrast agent has excellent clinical feedback and
good imaging results. In 1998, Iohexol Injection was launched as Beilu's 1st
iodinated Contrast Media.

Product name: Iohexol Injection

Generic name: Iohexol Injection

Type: Injectable Contrast Media for CT/X-ray

Ingredients: Iohexol

Specification:

(1) 20 ml: 6 gI (2) 50 ml: 15 gI

(3) 75 ml: 22.5 gI (4) 100 ml: 30 gI

(5) 20 ml: 7 gI (6) 50 ml: 17.5 gI

(7) 100 ml: 35 gI

Administration: For injection or oral use of iodinated contrast

Adverse reactions: See the details from the package insert

Shelf life: 36 months

Indications of Iohexol Injection
The omnipaque iohexol is an X-ray contrast agent. It can be used for
angiocardiography, arteriography, urography, enhanced CT examination inclduing
cervical, thoracic and lumbar myelography, CT cisternography following
intrathecal injection (i.e., an injection into the subarachnoid space);
arthrography, endoscopic retrograde cholangiopancreatography (ERCP),
herniography or fistulography, hysterosalpingography, sialography, percutaneous
transhepatic cholangiography (PTC), sinography, gastroenterography, T-tube
angiography, etc.

Precautions of Iohexol Injection
General precautions for the use of nonionic-monomer contrast agent:

1. Special attention should be paid to patients with allergies, asthma and
adverse reactions to iodinated contrast agents. Prophylactic medications such
as steroids and H1/H2 histamine receptor antagonists may be considered for
these patients.

2. The risk of serious reactions related to this type of CT contrast agent is
low. However, iodinated contrast agents can provoke anaphylactoid reactions or
other allergic reactions. Therefore, first aid measures should be trained in
advance, and necessary rescue drugs and devices should be prepared for possible
serious reactions.

3. In view of the low accuracy of pre-test in predicting allergic reactions
caused by nonionic contrast agents and the possibility that the pre-test itself
may lead to serious allergic reactions, it is not recommended to use pretest to
predict iodine allergic reactions.

4. Venous access should be kept smooth throughout the X-ray examination.

5. In the in-vitro tests, the effect of nonionic contrast agents on the
coagulation system is lighter than that of ionic contrast agents. During
angiography, great care should be taken in the intravascular technical
procedures, and the catheter should be irrigated with heparinized saline from
time to time to reduce the thrombosis and embolism related to the technical
procedures.

6. Patients, especially patients with multiple myeloma, diabetes, renal
insufficiency, infants and young children, and the elderly, must be
appropriately hydrated before and after the use of contrast agent. Electrolyte
disturbance and hemodynamic disorders are common in infants (< 1 year old),
particularly neonates. Special attention should be paid to patients with
serious heart diseases and pulmonary arterial hypertension because they are
prone to developing hemodynamic disorders and cardiac rhythm disturbances.

7. Patients with acute encephalopathy, brain tumour or history of epilepsy
should be prevented from seizures, and special attention should be paid to
them. The risks of seizures and neurologic reactions are significantly
increased in patients with alcohol or drug abuse. Transient hearing loss or
deafness occurs in a few patients after myelography, which is possibly caused
by a decrease in CSF pressure after lumbar puncture.

8. In view of the high risks of acute renal failure after the use of contrast
agent, special attention should be paid to patients with pre-existing renal
impairment and diabetes and patients with atypical globulinemia (multiple
myelomatoses and Waldenstrom macroglobulinemia).

9. Preventive actions include:

Identify patients with high-risk factors.

Ensure patients are appropriately hydrated and, if necessary, the infusion may
be maintained intravenously prior to examination until the contrast agent is
cleared from the kidneys.

Avoid any nephrotoxic agent, oral gallbladder contrast agent, surgery for
arterial occlusion, renal angioplasty or other major surgeries that increase
the renal burden until the contrast agent is cleared.

Repeat radiographic testing is delayed until renal function returned to the
pre-examination level.

To prevent lactic acidosis, the level of serum creatinine must be determined
before intravascular injection of iodinated contrast agent into diabetic
patients taking metformin. For patients with abnormal serum creatinine/renal
function, metformin must be discontinued and the examinations with contrast
agent must be postponed until after 48 hours of discontinuation. Metformin
should be reused only after renal function and serum creatinine level are
constant. In some emergency cases of patients with abnormal or unknown renal
function, the physician must assess both advantages and disadvantages of using
contrast agent and take precautions, such as discontinuation of metformin,
adequate hydration of patients, testing of renal functions, and careful
observation of symptoms of lactic acidosis.

There is a potential risk of transient hepatic dysfunction. Special attention
should be paid to patients with serious hepatic and renal insufficiency due to
significantly longer time to clear contrast agent. Hemodialysis patients may
receive the examinations with contrast agents. Immediate hemodialysis is not
necessary after the injection of contrast agent because there is no evidence
showing that hemodialysis can protect patients with renal impairment from
contrast-induced nephropathy.

Iodinated contrast agents may exacerbate symptoms of myasthenia gravis.
Patients with pheochromocytoma should be treated with α-blockers to prevent
hypertensive crisis in interventional procedures. Special attention should also
be paid to patients with hyperthyroidism. Patients with multinodular goitre may
develop hyperthyroidism after using iodinated contrast agents. The possibility
of transient hypothyroidism in preterm infants after using contrast agents
should be clearly recognized.

Contrast media extravasation (CME) occasionally causes localized pain or
oedema, which gradually subsides without sequelae. However, inflammation and
even tissue necrosis may occasionally occur. Routine treatment is to elevate
the affected limb and cold-compress at local sites. Surgical decompression is
required in case of compartment syndrome.

This type of Iohexol contrast agent should be drawn into the barrel before use.
Each vial is for single use only, and the unused portion should be discarded.

Beilu is a professional contrast media manufacturing companies, we provide ct
contrast medium, iohexol package insert, omnipaque package insert and etc. Want
to know more? Please contact us.

Minimum Order: 20 bags

Click to Enlarge